Table 4.
Radiographic progression in the spine in the FORCAST study population according to the presence/absence of definite MRI lesions in the sacroiliac joints at baseline
| SPARCC SIJ≥2* |
SSS fat metaplasia ≥2 |
SSS erosion ≥2 |
SSS backfill ≥2 |
SSS ankylosis ≥2 |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes N=103 |
No N=126 |
p Value | Yes N=78 |
No N=154 |
p Value | Yes N=73 |
No N=159 |
p Value | Yes N=58 |
No N=174 |
p Value | Yes N=82 |
No N=150 |
p Value | |
| All patients | |||||||||||||||
| ΔmSASSS units/year (mean (SD)) | 0.74 (1.11) | 0.94 (1.50) | 0.43 | 1.09 (1.51) | 0.73 (1.23) | 0.06 | 0.56 (1.01) | 0.98 (1.44) | 0.01 | 0.89 (1.19) | 0.84 (1.38) | 0.33 | 1.12 (1.63) | 0.70 (1.12) | 0.01 |
| Patients on standard therapy (N=98) | |||||||||||||||
| Yes N=45 |
No N=51 |
p Value | Yes N=30 |
No N=68 |
p Value | Yes N=31 |
No N=67 |
p Value | Yes N=21 |
No N=77 |
p Value | Yes N=27 |
No N=71 |
p Value | |
| ΔmSASSS units/year (mean (SD)) | 0.76 (1.26) | 0.77 (1.08) | 0.63 | 1.24 (1.56) | 0.57 (0.86) | 0.03 | 0.53 (0.82) | 0.89 (1.27) | 0.19 | 1.15 (1.47) | 0.67 (1.04) | 0.07 | 0.93 (1.18) | 0.72 (1.14) | 0.15 |
| Patients on TNFi therapy (N=134) | |||||||||||||||
| Yes N=58 |
No N=75 |
p Value | Yes N=48 |
No N=86 |
p Value | Yes N=42 |
No N=92 |
p Value | Yes N=37 |
No N=97 |
p Value | Yes N=55 |
No N=79 |
p Value | |
| ΔmSASSS units/year (mean (SD)) | 0.73 (0.99) | 1.06 (1.73) | 0.53 | 0.99 (1.48) | 0.86 (1.45) | 0.51 | 0.59 (1.15) | 1.05 (1.56) | 0.04 | 0.75 (0.99) | 0.96 (1.60) | 0.88 | 1.22 (1.81) | 0.69 (1.11) | 0.03 |
*Available SPARCC SIJ scores n=229.
FORCAST, Follow Up Research Cohort in Ankylosing Spondylitis; SPARCC, Spondyloarthritis Research Consortium of Canada; SSS, SPARCC MRI SIJ Structural Scoring; TNFi, tumour necrosis factor inhibitor.